At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 537 enrolled
Drug / intervention
Venlafaxine ER +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Patient Outcomes With Education, Drug Therapy, and Support (POETS): A Multicenter, Open-label, Randomized Study to Evaluate Depressed Subjects Treated With Venlafaxine Extended-release vs. Venlafaxine Extended-release Plus the Dialogues Time to Talk Program in a Primary Care Setting
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Nov 20, 2006·Updated Apr 23, 2012
In Brief
A Phase 4 clinical trial evaluating Venlafaxine ER and Dialogues Time to Talk Program for Depressive Disorder, Major. Completed, enrolled 537 participants across 44 sites.
Detailed Summary
The purpose of this study is to evaluate the effect of the Dialogues Time to Talk program in subjects treated with Venlafaxine Extended Release (ER). Dialogues Time to Talk Program is a patient management program, which aims to help patients achieve successful outcomes by reinforcing physician treatment efforts, providing feedback to treating physicians, and encouraging better physician-patient communications.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Major
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedNov 2006
Study CompletionOct 2007
TodayJul 2026
First PostedNov 20, 2006
Enrollment StartJun 1, 2006
Study CompletionOct 1, 2007
TodayJul 2, 2026
Posted 19.6 years ago
Interventions
Venlafaxine ERdrug
Dialogues Time to Talk Programbehavioral